About: Caspofungin for primary antifungal prophylaxis after T‐cell–replete haploidentical stem cell transplantation with post‐transplant cyclophosphamide

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Caspofungin for primary antifungal prophylaxis after T‐cell–replete haploidentical stem cell transplantation with post‐transplant cyclophosphamide Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Caspofungin for primary antifungal prophylaxis after T‐cell–replete haploidentical stem cell transplantation with post‐transplant cyclophosphamide
Creator	Santoro, Armando Bramanti, Stefania Casari, Erminia De Philippis, Chiara Mariotti, Jacopo Pocaterra, Daria Sarina, Barbara Tordato, Federica Carlo-Stella, Carmelo Luca Castagna, \|
Source	Medline; PMC
abstract	OBJECTIVES: T‐cell–replete haploidentical stem cell transplantation (Haplo‐SCT) with post‐transplant cyclophosphamide (PT‐Cy) is at high risk of invasive fungal infections (IFI), and anti‐mold–active drug is required for primary antifungal prophylaxis (PAP) according to international guidelines. No data are available on the efficacy of caspofungin as PAP in this setting. METHODS: Here, we report our retrospective experience with 103 consecutive patients treated with caspofungin as PAP after Haplo‐SCT. Caspofungin was administered only during the pre‐engraftment phase. RESULTS: Hundred‐day cumulative incidence of proven‐probable IFI (PP‐IFI) was 8.7% and median day of onset was 19 post‐SCT. No patient died of PP‐IFI, and overall survival (OS) and non‐relapse mortality (NRM) hazard ratio (HR) for patients experiencing IFI were 1.02 (P = 0.9) and 0.7 (P = 0.7), respectively. Three‐year overall survival (OS) and 1‐year non‐relapse mortality (NRM) were 55% and 19%, respectively. By univariate analysis, duration of neutropenic phase and partial remission pre‐transplant disease status were associated with increased incidence of IFI, but were not confirmed by multivariate analysis. CONCLUSION: In summary, PAP with caspofungin is an effective strategy for preventing IFI in the context of Haplo‐SCT with PT‐Cy. Further efforts are required in order to identify more potent strategies able to avoid the occurrence of breakthrough infections.
has issue date	2019-02-13(xsd:dateTime)
bibo:doi	10.1111/ejh.13214
bibo:pmid	30672611
has license	no-cc
sha1sum (hex)	a90d619d526e3b78effd53c1d5b4deeacbf0adf1
schema:url	https://doi.org/10.1111/ejh.13214
resource representing a document's title	Caspofungin for primary antifungal prophylaxis after T‐cell–replete haploidentical stem cell transplantation with post‐transplant cyclophosphamide
has PubMed Central identifier	PMC7163667
has PubMed identifier	30672611
schema:publication	Eur J Haematol
resource representing a document's body	covid:a90d619d526e3b78effd53c1d5b4deeacbf0adf1#body_text
is schema:about of	named entity 'transplantation' named entity 'cyclophosphamide' named entity 'steroid' named entity 'patients' named entity 'IFIs' named entity 'transplantation' named entity 'IFIs' named entity 'cumulative incidence' named entity 'fungal infections' named entity 'T-cell' named entity 'autologous' named entity 'multivariate analysis' named entity 'High-dose' named entity 'non-myeloablative' named entity 'relapse' named entity 'fludarabine' named entity '14.5' named entity 'total body irradiation' named entity 'epidemiologic studies' named entity 'GVHD' named entity 'cumulative incidence' named entity 'myeloablative' named entity 'PBSC' named entity 'steroids' named entity 'ANC' named entity 'neutropenic' named entity 'primary endpoint' named entity 'relapse' named entity 'Cox regression models' named entity 'Kaplan-Meier method' named entity 'fungal infection' named entity 'bone marrow' named entity 'NIH' named entity 'fludarabine' named entity 'risk factors' named entity 'GVHD' named entity 'neutropenia' named entity 'cumulative incidence' named entity 'T-cell' named entity 'neutropenia' named entity 'caspofungin' named entity 'Baltimore' named entity 'fluconazole' named entity 'confidence intervals' named entity 'RIC' named entity 'Antifungal prophylaxis' named entity 'fluconazole' named entity 'Institutional Review Board' named entity 'fungal infection' named entity 'Platelet' named entity 'echinocandin' named entity '95% confidence interval' named entity 'stem cell' named entity 'voriconazole' named entity 'prophylaxis' named entity 'progression-free survival' named entity 'cumulative incidence' named entity 'mycophenolate' named entity 'busulfan' named entity 'HLA-A' named entity 'EZR' named entity 'itraconazole' named entity '21 days' named entity 'immunosuppressive' named entity 'aGVHD' named entity 'caspofungin' named entity 'CMV infection' named entity 'Candida' named entity 'ECIL' named entity 'GVHD' named entity 'PBSC' named entity 'prospective study'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software